• 
• Print
• Email
• Order a PDF

New Haven biopharma Kolltan Pharmaceuticals said it has licensed antibody technology developed by one of its founders and a member of its scientific advisory board.

The so-called anti-KIT receptor tyrosine kinase antibodies were developed in the labs of Joseph Schlessinger at Yale University — a Kolltan founder — and Sachdev Sidu, a geneticist at the University of Toronto and Kolltan adviser.

Terms of the deal were not disclosed.

• 
• Print
• Email
• Order a PDF